Objective Population-based data are lacking regarding the risk of overall and cause-specific mortality across the complete histological spectrum of non-alcoholic fatty liver disease (NAFLD). Design ...

Once considered a niche concern, it is now a growing global epidemic affecting more than one in four adults worldwide.

Dapagliflozin effectively treats fatty liver disease (MASH), reducing liver fat and scarring. Black patient involvement in ...

Individuals with diabetes and hypertension are especially at risk and should undergo screening for NAFLD (Non-Alcoholic Fatty ...

By Dr. Jaisingh Rajput Nonalcoholic fatty liver disease (NAFLD) is an increasingly prevalent condition affecting individuals ...

A diabetes drug, dapagliflozin, has shown promise in treating fatty liver disease by reducing liver fat and scarring, ...

The limitations of a liver biopsy have led to considerable interest and attempts to diagnose this condition with laboratory tests and imaging modalities. The definitive diagnosis of NAFLD is based ...

Non-alcoholic fatty liver disease is predicted to become the leading indicator for liver transplant necessity within the ...

Once considered a niche concern, it is now a growing global epidemic affecting more than one in four adults worldwide.

Dapagliflozin, a SGLT2 inhibitor used for type 2 diabetes, alleviates steatohepatitis and fibrosis in patients with ...